Emergent BioSolutions Inc

Emergent BioSolutions Inc. a life sciences company focuses on the provision of preparedness and response solutions that address accidental deliberate and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs which include chemical biological radiological nuclear and explosives; emerging infectious diseases; travel health; public health crises; and acute emergency and community care. The company offers ACAM2000 a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax an anthrax vaccine; Ebanga a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif an oral vaccine for typhoid fever; and Vaxchora a single-dose oral vaccine to treat cholera. In addition the company is developing AV7909 an anthrax vaccine; CGRD-001 a pralidoxime chloride/atropine auto-injector; CHIKV VLP a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001 a diazepam auto-injector; SIAN an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu a universal influenza vaccine. Further it provides contract development and manufacturing services comprising drug substance and product manufacturing and packaging as well as technology transfer process and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg Maryland.